Discontinued — last reported Q4 '25
Manhattan Bridge Capital Free cash flow decreased by 19.7% to $1.12M in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 11.6%, from $1.27M to $1.12M. This decline may warrant attention — for this metric, higher values are generally preferred.
An increase suggests improved operational efficiency or reduced capital intensity, providing more flexibility for capital allocation. A decrease may indicate higher investment in R&D or infrastructure, or potential challenges in converting earnings into cash.
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and m...
Large-cap medical device and pharmaceutical peers typically maintain strong, positive free cash flow, though levels vary based on the intensity of R&D spending and the lifecycle stage of major product lines.
free_cash_flow| Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q3 '24 | Q4 '24 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Value | $1.17M | $1.15M | $1.31M | $1.40M | $1.42M | $1.26M | $1.23M | $1.27M | $1.40M | $1.12M |
| QoQ Change | — | -2.2% | +14.2% | +7.1% | +1.2% | -11.4% | -2.0% | +3.1% | +10.1% | -19.7% |
| YoY Change | — | — | — | — | +21.1% | +9.7% | -13.1% | +1.0% | +13.5% | -11.6% |